September 29, 2016 2:54 AM ET

Healthcare Providers and Services

Company Overview of Clarient, Inc.

Company Overview

Clarient, Inc. provides oncology testing and diagnostic services in the United States. The company focuses on breast cancer testing, breast cancer recurrence testing, colon cancer testing, KRAS in colorectal cancer, KRAS and BRAF testing in colorectal cancer, KRAS mutation analysis, KRAS mutation testing, and pulmotype test. Its tests include ALK Rearrangement by FISH, BRAF, BRAF V600 mutation-melanoma, EGFR mutation analysis, KRAS and BRAF, KRAS mutation analysis, Mammostrat, and PI3K. The company also develops diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Its customers include pathologists, oncologists, hospitals, and biopharmaceuti...

31 Columbia

Aliso Viejo, CA 92656-1460

United States

Founded in 1993

Phone:

949-425-5700

Fax:

949-425-5865

Key Executives for Clarient, Inc.

Chief Executive Officer
Managing Director, Consulting Pathologist and Member of Scientific Advisory Board
Chief Financial Officer
Chief Compliance Officer & Privacy Officer, General Counsel and Vice President
Chief Operating Officer of Clarient Pathology Services
Compensation as of Fiscal Year 2016.

Clarient, Inc. Key Developments

Clarient Diagnostic Services, Inc., Clarient, Inc., Neogenomics Inc. - M&A Call

To discuss the agreement to acquire Clarient, Inc., and its wholly-owned subsidiary Clarient Diagnostic Services, Inc.

Clarient and Glaxo Smith Kline to Create a Force in Cancer Testing

Clarient and Glaxo Smith Kline will create a force in cancer testing. GE Healthcare, Clarient and GSK will certify laboratories around the world to perform cancer diagnostic tests with initial network labs expected in 2015. Clarient's own laboratory expertise includes immuno histochemistry (IHC), flow cytometery, qPCR, (fluorescent) in-situ hybridization ([F]ISH), cytogenetic karyotyping, microarrays, and next-generation sequencing (NGS). Lab testing networked by GE Healthcare and Clarient will focus initially on 70 melanoma-specific mutations, including the companion diagnostics (CDx)-targeted BRAF V600E and V600K genes. Testing performed at networked labs will feed an associated data analytics service to be made available by GE Healthcare as a subscription. GSK will presumably be provided the same service to aid its activities in biopharmaceutical development. The GE-Clarient-developed lab and data analytics service will be available to clients including pharmaceutical market participants, payers and other healthcare organizations.

Similar Private Companies By Industry

Company Name Region
@ Home Medical, Inc. United States
@home approach, llc United States
@Home Care United States
1011 E. Pecan Grove Road, LLC United States
1125 Sir Francis Drake Boulevard Operating Company, Llc United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
October 21, 2015
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Clarient, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.